Clinical trials: Prostatic Disease
Prostate Cancer
Ultrasound in Treating Patients With Recurrent Stage I or Stage II Prostate Cancer
RATIONALE: Ultrasound therapy kills tumor cells by heating them to several degrees above body temperature. This treatment may be effective for prostate cancer.
- Trial name
- NCT00005075
- Testing
- high-intensity focused ultrasound ablation
- Where
- 2 sites in United States
- Sponsor
- EDAP Technomed
Prostatic Neoplasms, Prostate Cancer
Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study
This study aims to evaluate the diagnostic performance of [68Ga]Ga-OncoACP3 PET imaging, which targets prostate acid phosphatase (ACP3), in men with clinically suspected or confirmed high-risk prostate cancer, or suspected…
- Trial name
- NCT07830212
- Testing
- [68Ga]Ga-OncoACP3
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yong He
Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
This trial studies how well 68Ga-PSMA-11 PET scan works in imaging patients with prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET may find and diagnose prostate cancer and improve monitoring of treatment response.
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
- Trial name
- NCT04777071
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- University of Washington
Prostate Calcification
MR Imaging of Prostatic Calcifications
Prostate calcifications can limit evaluation of the prostate due to artifact on MRI, and can limit therapy by blocking therapeutic ultrasound.
- Trial name
- NCT03625336
- Testing
- MRI
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Organic, Including Symptomatic, Mental Disorders, Substance Use
Exploring the Comorbidity Between Mental Disorders and General Medical Conditions
Mental disorders have been shown to be associated with a number of general medical conditions (also referred to as somatic or physical conditions).
- Conditions
- Organic, Including Symptomatic, Mental Disorders, Substance Use, Schizophrenia, Mood [Affective] Disorders
- Trial name
- COMO-GMC (NCT03847753)
- Testing
- Organic Disorders, Substance Use Disorders, Schizophrenia Disorders
- Volunteers
- 5,940,299 people
- Sponsor
- University of Aarhus
Prostate Cancer
Hypo-fractionated Postoperative IMRT in Prostate Cancer
To report the outcome of hypo-fractionated radiotherapy after radical prostatectomy (RP) for prostate cancer (PCa) using IMRT-SIB.
- Trial name
- NCT03233672
- Testing
- Hypo-fractionated postoperative IMRT-SIB
- Volunteers
- 124 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction.
- Conditions
- Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT04267575
- Testing
- Canady Helios Cold Plasma Scalpel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jerome Canady, M.D.
Prostatic Neoplasms, Castration-Resistant
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
The overall aim of the trial is to investigate the safety and anti-tumour activity of an experimental drug BI 836845 taken together with the prostate cancer drug, enzalutamide, compared to enzalutamide given alone, in castrate…
- Trial name
- NCT02204072
- Testing
- BI 836845, Enzalutamide
- Where
- 27 sites in United States, Hong Kong and 6 more
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Prostate Cancer
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate it's ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy…
- Trial name
- PSMA BCR (NCT02918357)
- Testing
- Ga-68 labeled PSMA-11 PET
- Where
- United States
- Volunteers
- 385 people
- Sponsor
- University of California, San Francisco
Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection
Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration
The purpose of this study is to demonstrate the prostatic diffusion in significant concentration of ertapenem achieved after a pre-operative single administration.
- Trial name
- ERTAPRO (NCT02041767)
- Testing
- Ertapenem
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prostate Cancer
A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer
This is the first study of MLN2704 administered to humans. The purpose of the study is to determine the highest dose of MLN2704 that can be given safely to patients with prostate cancer, and to identify any side effects…
- Trial name
- NCT00052000
- Testing
- MLN2704 (DM1 conjugated monoclonal antibody MLN591)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Cancer, Angiosarcoma
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1…
- Conditions
- Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer
- Trial name
- NCT03860272
- Testing
- Botensilimab, Balstilimab
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 499 people
- Sponsor
- Agenus Inc.
Prostate Cancer
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
To gather information on the safety of monotherapy of Casodex® tablets 80 mg, targeting prostate cancer patients who have no history of having received treatment by either endocrine therapy (including surgical castration).
- Trial name
- CAMON (NCT00919477)
- Where
- 160 sites in Japan
- Volunteers
- 712 people
- Sponsor
- AstraZeneca
Prostate Cancer
Circulating Tumor Cells in Prostate Cancer Patients
The purpose of this study is to determine if a non-invasive cancer treatment, high-dose stereotactic body radiotherapy (SBRT), is associated with changes in circulating tumor cells counts in patients with low- and…
- Trial name
- NCT01414712
- Testing
- Blood Drawing
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Texas Southwestern Medical Center
Benign Prostatic Hyperplasia
Procedure Transurethral Needle Ablation (TUNA) and Hospitalization of Short Duration
The TUNA is a known and already old technique. There exists, in the literature, a certain number of studies showing the long-term effectiveness (5 years), evaluated on the IPS and the flow mictional.This effectiveness is slightly…
- Trial name
- EPURE (NCT00890851)
- Testing
- Transurethral Needle Ablation (TUNA)
- Where
- France
- Volunteers
- 53 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prostate Cancer
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA after radiation therapy and identify biomarkers related to…
- Trial name
- NCT00899912
- Testing
- microarray analysis, diagnostic laboratory biomarker analysis
- Where
- 10 sites in United States
- Volunteers
- 13 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00984919
- Testing
- high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Ovarian Neoplasms, Prostatic Neoplasms
A Study of DM002 in Patients With Advanced Solid Tumors
The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug.
- Conditions
- Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Colorectal Neoplasms
- Trial name
- NCT06751329
- Testing
- DM002
- Where
- 7 sites in United States, Australia
- Volunteers
- 280 people
- Sponsor
- Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Benign Prostatic Hyperplasia
The Changes of Urine Growth Factors Level
The Changes of Urine Growth Factors Level in Patients With Benigh Prostate Hyperplasia after medical treatment.
- Trial name
- NCT06282731
- Testing
- Silodosin
- Where
- Taiwan
- Volunteers
- 74 people
- Sponsor
- En Chu Kong Hospital
Prostate Cancer
Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.
The purpose of this clinical research study is to assess the safety and efficacy of an investigational therapy called DCVax(TM)-Prostate.
- Trial name
- NCT00043212
- Testing
- Dendritic cell immunotherapy
- Where
- 16 sites in United States
- Sponsor
- Northwest Biotherapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.